Psilocybin and psilocin research index

Select for export

Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms.

Interest in the therapeutic potential of serotonergic psychedelic compounds including psilocybin has surged in recent years. While human clinical research suggests psilocybin holds promise as a rapid and long-lasting antidepressant, little is known about how its acute mechanisms of action mediate enduring alterations in cognition and behavior. Human neuroima...

Details DOI 10.1007/s00213-022-06297-0 PubMed 36564671 Copy citation Copy BibTeX

Unknown journal 2022-12-23 Meccia J, Lopez J, Bagot RC.

Europe PMC Published psilocybin DepressionNeuroplasticityBrain Imaging Review Article Brain More

Select for export

The psychedelic renaissance: can psilocybin possibly combat depression?

Mental health disorders such as depression and anxiety are major contributors to the overall global health burden. COVID-19 has further aggravated mental health disorders and also increased substance abuse due to lockdowns1. The Global Burden of Disease reported that the pandemic has led to a 27.6% increase in cases of major depressive disorder (MDD) and a 2...

Details DOI 10.1097/gh9.0000000000000089 Copy citation Copy BibTeX

International Journal of Surgery Global Health 2022-10-31 Hamna Raheel, Unaiza Naeem, Asim Shaikh, Omer Ahmed Shaikh

OpenAlex Published psilocybin DepressionAnxietyPTSD Systematic Review Psilocybin More

Select for export

Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis.

BackgroundPsychedelic therapy shows promise for Major Depressive Disorder, especially when treatment-resistant, as well as life-threatening illness distress. The objective of this systematic review, inclusive of meta-analysis, is to examine recent clinical research on the therapeutic effects of classic psychedelics on depressive symptoms.MethodsFourteen psyc...

Details DOI 10.1016/j.jad.2022.09.168 PubMed 36209780 Copy citation Copy BibTeX

Unknown journal 2022-10-06 Ko K, Kopra EI, Cleare AJ, Rucker JJ.

Europe PMC Published psilocybin DepressionEnd-of-Life DistressClinical Trial Randomized Controlled Trial Humans More

Select for export

Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing

Background: Therapeutic administration of psychedelic drugs has shown significant potential in historical accounts and in recent clinical trials in the treatment of depression and other mood disorders. A recent randomized double-blind phase-IIb study demonstrated the safety and efficacy of COMP360, COMPASS Pathways’ proprietary synthetic formulation of psilo...

Details DOI 10.31234/osf.io/kh3cx Copy citation Copy BibTeX

PsyArXiv 2022-09-29 Dougherty RF, Clarke P, Alti M, Kuc J, Schlosser D, Dunlop BW

PsyArXiv PREPRINT (not peer reviewed) psilocybin DepressionMechanism of ActionEmotional Processing Clinical Trial More

Select for export

Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing

Background: Therapeutic administration of psychedelic drugs has shown significant potential in historical accounts and in recent clinical trials in the treatment of depression and other mood disorders. A recent randomized double-blind phase-IIb study demonstrated the safety and efficacy of COMP360, COMPASS Pathways’ proprietary synthetic formulation of psilo...

Details Copy citation Copy BibTeX

PsyArXiv 2022-09-29 Authors unavailable

PsyArXiv PREPRINT (not peer reviewed) psilocybin DepressionMechanism of ActionEmotional Processing Clinical Trial Depression More

Select for export

Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.

This publication discusses two compounds belonging to the psychoactive substances group which are studied in the context of depression treatment-psilocybin and esketamine. The former is a naturally occurring psychedelic. The latter was invented in the laboratory exactly 60 years ago. Although the substances were controversial in the past, recent studies indi...

Details DOI 10.3390/ijms231911450 PubMed 36232748 Copy citation Copy BibTeX

Unknown journal 2022-09-27 Psiuk D, Nowak EM, Dycha N, Łopuszańska U, Kurzepa J, Samardakiewicz M.

Europe PMC Published psilocybin DepressionSystematic ReviewReview Article Systematic Review Humans More

Select for export

Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP001 And COMP003 Trials (P-TRD LTFU)

The primary objective of this study is to assess the long-term efficacy of psilocybin with respect to use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS) over a total of 52 weeks (compared across the 1 mg, 10 mg and 25 mg psilocybin gr...

Details Copy citation Copy BibTeX

ClinicalTrials.gov 2022-09-21 COMPASS Pathways

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionTreatment-Resistant DepressionSafety Other Treatment Resistant Depression More

Select for export

Towards an understanding of psychedelic-induced neuroplasticity.

Classic psychedelics, such as LSD, psilocybin, and the DMT-containing beverage ayahuasca, show some potential to treat depression, anxiety, and addiction. Importantly, clinical improvements can last for months or years after treatment. It has been theorized that these long-term improvements arise because psychedelics rapidly and lastingly stimulate neuroplas...

Details DOI 10.1038/s41386-022-01389-z PubMed 36123427 Copy citation Copy BibTeX

Unknown journal 2022-09-18 Calder AE, Hasler G.

Europe PMC Published psilocybin DepressionAnxietyAddiction Review Article Humans More

Select for export

Microdosing psilocybin for chronic pain: a case series.

AbstractPsychedelic serotonergic agonists such as psilocybin have recently been shown to produce sustained benefit in refractory depression, end of life anxiety, and addiction when administered in hallucinogenic doses and coupled with psychotherapy. Although it has been suggested that similar high-dose protocols may help chronic pain conditions, there are fe...

Details DOI 10.1097/j.pain.0000000000002778 PubMed 36066961 Copy citation Copy BibTeX

Pain 2022-09-04 Lyes M, Yang KH, Castellanos J, Furnish T.

Europe PMC Published psilocybin DepressionAnxietyAddiction Clinical Trial Humans More

Select for export

Sustained effects of single doses of classical psychedelics in humans.

The serotonergic classical psychedelics include compounds that primarily activate the brain's serotonin 2 A receptor (5-HT2AR), such as LSD, psilocybin, and DMT (ayahuasca). The acute effects of these compounds are well-known as are their ability to increase the emotional state both in healthy people and in those with neuropsychiatric disorders. In particula...

Details DOI 10.1038/s41386-022-01361-x PubMed 35729252 Copy citation Copy BibTeX

Unknown journal 2022-06-20 Knudsen GM.

Europe PMC Published psilocybin DepressionAnxietyNeuroplasticity Review Article Brain More

Select for export

Neuropharmacological analysis of the anti-addictive and therapeutic effects of psilocybin

This review presents a general background of psilocybin pharmacology and discusses its uses in treating various mental health disorders such as depression, anxiety, obsessive-compulsive disorder, and addiction. A summary of preliminary clinical trials utilizing psilocybin in each disorder is presented, along with an analysis of the neurobiological mechanisms...

Details DOI 10.21083/surg.v14i1.6870 Copy citation Copy BibTeX

SURG Journal 2022-05-31 Anthony Principe

OpenAlex Published psilocybin DepressionAnxietyAddiction Clinical Trial Psilocybin More

Select for export

Psilocybin-Assisted Therapy Found to Improve Depression, Offer Other Benefits

Back to table of contents Previous article Next article Clinical & ResearchFull AccessPsilocybin-Assisted Therapy Found to Improve Depression, Offer Other BenefitsRichard KarelRichard KarelSearch for more papers by this authorPublished Online:23 May 2022https://doi.org/10.1176/appi.pn.2022.06.6.30AbstractA small study involving 24 participants found that psi...

Details DOI 10.1176/appi.pn.2022.06.6.30 Copy citation Copy BibTeX

Psychiatric News 2022-05-22 Richard Karel

OpenAlex Published psilocybin DepressionAnxietyEnd-of-Life Distress Clinical Trial Psilocybin More

Select for export

The Efficacy of Psilocybin in the Treatment of Depression andAnxiety: A Meta-Analysis

Background: The use of psychedelic compounds to treat psychiatric disorders has become a very significant topic of research over the past several years. Psilocybin has risen to prominence as one of the most studied among these psychedelic compounds. Multiple trials have already shown that it can be a safe and efficacious treatment for various medical conditi...

Details DOI 10.2174/2666082218666220513142002 Copy citation Copy BibTeX

Current Psychiatry Research and Reviews 2022-05-15 Andrew Hodge, Suporn Sukpraprut-Braaten, Robert Strayhan

OpenAlex Published psilocybin DepressionAnxietyReceptor Pharmacology Randomized Controlled Trial Psilocybin More

Select for export

Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer.

Opinion statementPreventing depression in cancer patients on long-term opioid therapy should begin with depression screening before opioid initiation and repeated screening during treatment. In weighing the high morbidity of depression and opioid use disorder in patients with chronic cancer pain against a dearth of evidence-based therapies studied in this po...

Details DOI 10.1007/s11864-022-00954-4 PubMed 35254595 Copy citation Copy BibTeX

Unknown journal 2022-03-06 Bates N, Bello JK, Osazuwa-Peters N, Sullivan MD, Scherrer JF.

Europe PMC Published psilocybin DepressionAddictionEnd-of-Life Distress Other Humans More

Select for export

Psilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice.

Serotonergic psychedelic drugs, such as psilocin (4-hydroxy-N,N-dimethyltryptamine), profoundly alter the quality of consciousness through mechanisms which are incompletely understood. Growing evidence suggests that a single psychedelic experience can positively impact long-term psychological well-being, with relevance for the treatment of psychiatric disord...

Details DOI 10.1038/s41398-022-01846-9 PubMed 35197453 Copy citation Copy BibTeX

Translational Psychiatry 2022-02-22 Thomas CW, Blanco-Duque C, Bréant BJ, Goodwin GM, Sharp T, Bannerman DM

Europe PMC Published psilocybinpsilocin DepressionNeuroplasticityBrain Imaging Animal Study Brain More

Select for export

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.

BackgroundPreliminary data suggest that psilocybin-assisted treatment produces substantial and rapid antidepressant effects in patients with major depressive disorder (MDD), but little is known about long-term outcomes.AimsThis study sought to examine the efficacy and safety of psilocybin through 12 months in participants with moderate to severe MDD who rece...

Details DOI 10.1177/02698811211073759 PubMed 35166158 Copy citation Copy BibTeX

Journal of Psychopharmacology 2022-01-31 Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW

Europe PMC Published psilocybin DepressionWellbeingSpirituality Clinical Trial Humans More

Select for export

Human behavioral pharmacology of psychedelics.

The past decade has witnessed a rapid growth of research on the basic science and clinical understanding of psychedelics. This chapter provides an overview of the human behavioral pharmacology of psychedelics focusing on three prototypic classic psychedelics-psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT). A brief historical overvi...

Details DOI 10.1016/bs.apha.2021.10.003 PubMed 35341564 Copy citation Copy BibTeX

Unknown journal 2021-11-10 Strickland JC, Johnson MW.

Europe PMC Published psilocybin DepressionAddictionPharmacology Clinical Trial Humans More

Select for export

From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders.

The studies of psychedelics, especially psychedelic tryptamines like psilocybin, are rapidly gaining interest in neuroscience research. Much of this interest stems from recent clinical studies demonstrating that they have a unique ability to improve the debilitating symptoms of major depressive disorder (MDD) long-term after only a single treatment. Indeed, ...

Details DOI 10.1111/jnc.15509 PubMed 34519052 Copy citation Copy BibTeX

Unknown journal 2021-10-21 Kozlowska U, Nichols C, Wiatr K, Figiel M.

Europe PMC Published psilocybin DepressionAddictionNeuroplasticity Clinical Trial Humans More

Select for export

Psychedelics: A new era of treatment?

Introduction Psychedelics - including LSD (lysergic acid diethylamide), psilocybin, DMT (N, N-dimethyltryptamine), ayahuasca and mescaline - have an ancient history across various civilizations. In 1950, after LSD’s discovery by Hofmann, psychedelics enjoyed a short-lived relationship with psychiatry, before prohibitive legislature emerging in response to th...

Details Copy citation Copy BibTeX

Unknown journal 2021-08-12 Torres S.

Europe PMC Published psilocybin DepressionAnxietyAddiction Randomized Controlled Trial More

Select for export

Psilocybin: the magic medicine for depression?

Aims Depression is the single largest contributor to global disability. However, effective treatments are currently lacking, resulting in a significant burden of treatment-resistant depression (TRD). Psilocybin, a serotonergic psychedelic, found as the active compound in 'magic mushrooms', has been proposed as a novel therapeutic avenue for TRD. We aimed to ...

Details Copy citation Copy BibTeX

Unknown journal 2021-06-17 Corrigan A, Burchill E, Pelton L, Marrocu A, Mazzoleni A, Shackshaft L.

Europe PMC Published psilocybin DepressionBrain ImagingMechanism of Action Review Article More